On Wednesday, March 20, the Federal Circuit ruled that “discovery is not allowed in inter partes patent reexaminations.” The finding denies a bid by Cordis Corp. to subpoena Abbott Laboratories for discovery in an inter partes proceeding before the U.S. Patent and Trademark Office (USPTO). The decision noted that the Patent Act allows district courts to issue subpoenas in “any contested case” at the USPTO. The Federal Circuit found that reexaminations are not “contested.” Finnegan represented Abbott in this matter.
Award/Ranking
June 5, 2026
Award/Ranking
Finnegan Earns Top Rankings in 2026 IAM Patent 1000 Guide; Nearly 60 Attorneys Ranked
May 28, 2026
Commentary
May 20, 2026
Award/Ranking
Finnegan Partner Antje Brambrink Shortlisted for Women in Business Law EMEA Award
May 13, 2026
Press Release
Finnegan Secures Decisive ITC Victory for Innoscience in Final Determination
May 11, 2026
Award/Ranking
Associates Rank Finnegan “Best of the Best” in BTI Associate Satisfaction Survey
May 7, 2026
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.